Oramed Pharmaceuticals Analyst Ratings
Oramed Pharmaceuticals Analyst Ratings
While ratings are subjective and will change, the latest Oramed Pharmaceuticals (ORMP) rating was a downgraded with a price target of $0.00 to $0.00. The current price Oramed Pharmaceuticals (ORMP) is trading at is $2.25, which is out of the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 01/17/2023 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
| 01/12/2023 | — | Canaccord Genuity | Downgrades | Buy → Hold | |
| 05/16/2022 | 1233.33% | Aegis Capital | $35 → $30 | Maintains | Buy |
| 02/18/2022 | 788.89% | Cantor Fitzgerald | → $20 | Initiates Coverage On | → Overweight |
| 11/30/2021 | 1322.22% | HC Wainwright & Co. | $17 → $32 | Maintains | Buy |
| 11/29/2021 | 1322.22% | HC Wainwright & Co. | $17 → $32 | Maintains | Buy |
| 11/02/2021 | 1455.56% | Aegis Capital | $20 → $35 | Maintains | Buy |
| 07/29/2021 | 1233.33% | Canaccord Genuity | $27 → $30 | Maintains | Buy |
| 06/08/2021 | 788.89% | Aegis Capital | $12 → $20 | Maintains | Buy |
| 04/20/2021 | 1100% | Canaccord Genuity | → $27 | Initiates Coverage On | → Buy |
| 02/09/2021 | 922.22% | National Securities Corporation | → $23 | Initiates Coverage On | → Buy |
| 01/27/2021 | 433.33% | Aegis Capital | $6 → $12 | Maintains | Buy |
| 07/13/2020 | 655.56% | HC Wainwright & Co. | $16 → $17 | Reiterates | → Buy |
| 06/22/2020 | 611.11% | HC Wainwright & Co. | $20 → $16 | Maintains | Buy |
| 09/11/2019 | 211.11% | Ladenburg Thalmann | → $7 | Initiates Coverage On | → Buy |
| 日期 | 上/下行 | 分析師公司 | 价格目標變更 | 評級變更 | 上一頁/目前評分 |
|---|---|---|---|---|---|
| 01/17/2023 | — | HC 溫賴特 & 有限公司. | 降級 | 購買 → 中性 | |
| 01/12/2023 | — | 正確性 | 降級 | 購買 → 持有 | |
| 2022 年 5 月 16 日 | 1233.33% | 神盾資本 | 三十五美元 → 30 美元 | 維護 | 購買 |
| 2022 年 2 月 18 日 | 788.89% | 康托·菲茨杰拉德 | → 20 美元 | 啟動覆蓋範圍 | → 超重 |
| 2021 年 11 月 30 日 | 1322.22% | HC 溫賴特 & 有限公司. | 十七美元 → 三十二美元 | 維護 | 購買 |
| 11/29/2021 | 1322.22% | HC 溫賴特 & 有限公司. | 十七美元 → 三十二美元 | 維護 | 購買 |
| 11/02/2021 | 1455.56% | 神盾資本 | 二十美元 → 35 美元 | 維護 | 購買 |
| 2021 年 7 月 29 日 | 1233.33% | 正確性 | 二十七元 → 三十美元 | 維護 | 購買 |
| 2021 年 8 月 6 日 | 788.89% | 神盾資本 | 十二元 → 20 美元 | 維護 | 購買 |
| 04/20/2021 | 1100% | 正確性 | → 二十七美元 | 啟動覆蓋範圍 | → 購買 |
| 2021 年 9 月 2 日 | 922.22% | 國家證券公司 | → 二十三美元 | 啟動覆蓋範圍 | → 購買 |
| 2021 年 1 月 27 日 | 433.33% | 神盾資本 | 六元 → 十二美元 | 維護 | 購買 |
| 2020 年 7 月 13 日 | 655.56% | HC 溫賴特 & 有限公司. | 十六美元 → 17 美元 | 重申 | → 購買 |
| 2020 年 06 月 22 日 | 611.11% | HC 溫賴特 & 有限公司. | 二十元 → 十六美元 | 維護 | 購買 |
| 09/11/2019 | 211.11% | 拉登堡·塔爾曼 | → 7 美元 | 啟動覆蓋範圍 | → 購買 |
What is the target price for Oramed Pharmaceuticals (ORMP)?
有機藥品（ORMP）的目標價格是多少？
The latest price target for Oramed Pharmaceuticals (NASDAQ: ORMP) was reported by HC Wainwright & Co. on January 17, 2023. The analyst firm set a price target for $0.00 expecting ORMP to fall to within 12 months (a possible -100.00% downside). 4 analyst firms have reported ratings in the last year.
韋萊特有限公司於 2023 年 1 月 17 日報導了奧萊特製藥（納斯達克股票代碼：ORMP）的最新價格目標。該分析師公司將價格目標設定為 0.00 美元，預計 ORMP 將在 12 個月內跌至 12 個月內（下行可能為 -100.00％）。4 家分析師公司在去年報告了評級。
What is the most recent analyst rating for Oramed Pharmaceuticals (ORMP)?
Oramed 製藥（ORMP）的最新分析師評級是什麼？
The latest analyst rating for Oramed Pharmaceuticals (NASDAQ: ORMP) was provided by HC Wainwright & Co., and Oramed Pharmaceuticals downgraded their neutral rating.
奧萊特製藥公司（納斯達克股份代號：ORMP）的最新分析師評級由 HC 溫賴特公司提供，而奧瑞德製藥將其中性評級下調。
When is the next analyst rating going to be posted or updated for Oramed Pharmaceuticals (ORMP)?
Oramed 製藥（ORMP）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Oramed Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Oramed Pharmaceuticals was filed on January 17, 2023 so you should expect the next rating to be made available sometime around January 17, 2024.
分析師在進行了廣泛的研究後抵達股票評級，其中包括通過公共財務報表，與奧萊姆藥品的高管和客戶交談以及收聽盈利電話會議。大多數分析師每三個月這樣做一次，因此您應該每年每家公司獲得 4 個評級。對於 Oramed 製藥的最後一個評級提交了一月 17, 2023 所以你應該期望下一個評級將在一月左右提供 17, 2024.
Is the Analyst Rating Oramed Pharmaceuticals (ORMP) correct?
分析師評級 Oramed 藥品（ORMP）是否正確？
While ratings are subjective and will change, the latest Oramed Pharmaceuticals (ORMP) rating was a downgraded with a price target of $0.00 to $0.00. The current price Oramed Pharmaceuticals (ORMP) is trading at is $2.25, which is out of the analyst's predicted range.
儘管評級是主觀的並且會發生變化，但最新的 Oramed 藥品（ORMP）評級降級，目標價格為 0.00 美元至 0.00 美元。目前的價格 Oramed 製藥（ORMP）的交易價格為 2.25 美元，超出了分析師的預測範圍。
譯文內容由第三人軟體翻譯。
